Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study

Table 4 Response (ITT population)

	LD 5-FU (n = 7)	HD 5-FU (n = 45)	Total (n = 52)
Response rate (%)
Best overall response rate [95% CI]^a	57 [18, 90]	47 [32, 62]	48 [34, 62]
Stable disease	29	40	39
Progressive disease	14	9	10
Not assessable	0	4	4
Disease control rate (CR + PR + SD) (%) [95% CI]	86 [42, 100]	87 [73, 95]	87 [74, 94]
Median duration of response, days [95% CI]	7.7 [2.9, 12.2]	9.9 [8.1, 13.6]	9.9 [8.1, 11.4]

^aAll partial responses. LD = low-dose 5-FU; HD = high-dose 5-FU; CI = confidence intervals; CR = complete response; PR = partial response; SD = stable disease

ISSN: 1471-2407